INmune Bio Reports Q1 2026 Earnings with Reduced Net Loss
INmune Bio (NASDAQ: INMB) reported a net loss of $5.4 million for the first quarter of 2026, down from $9.7 million in the same period last year. The company also noted sufficient cash reserves to fund operations through Q1 2027 and provided updates on key developments related to its CORDStrom program.
Tickers: $INMB